- Home
- KIM vs GH Comparison
KIM vs GH Comparison
Compare KIM & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIM | GH |
|---|---|---|
| Founded | 1958 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.1B |
| IPO Year | 1991 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KIM | GH |
|---|---|---|
| Price | $20.15 | $101.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 21 |
| Target Price | $24.45 | ★ $82.76 |
| AVG Volume (30 Days) | ★ 4.5M | 2.2M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 5.16% | N/A |
| EPS Growth | ★ 57.13 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,123,057,000.00 | $902,569,000.00 |
| Revenue This Year | $5.64 | $34.72 |
| Revenue Next Year | $3.02 | $26.46 |
| P/E Ratio | $24.24 | ★ N/A |
| Revenue Growth | 8.14 | ★ 30.38 |
| 52 Week Low | $17.93 | $29.91 |
| 52 Week High | $25.06 | $112.43 |
Technical Indicators
Market Signals| Indicator | KIM | GH |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 55.40 |
| Support Level | $19.76 | $100.21 |
| Resistance Level | $20.47 | $109.59 |
| Average True Range (ATR) | 0.27 | 4.22 |
| MACD | 0.01 | -1.65 |
| Stochastic Oscillator | 36.62 | 13.51 |
Price Performance
Historical ComparisonAbout KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.